ReiThera and Exothera collaborate on vaccine manufacturing process


ReiThera and Exothera have entered into a collaboration agreement to develop a large-scale, low-cost-per-dose manufacturing process for the production of ReiThera’s novel vaccines.

The collaboration will be funded by a €3 million grant from the Bill & Melinda Gates Foundation to develop and deliver novel vaccines based on ReiThera’s GRAd technology platform, including against COVID-19 and HIV, primarily for low and middle income countries (LMIC) in Africa.

Large-scale manufacturing process will leverage Exothera’s unique expertise using NevoLineMT upstream platform (integrating scale-X with intensified structural fixed bedMT nitro bioreactor), developed by Exothera’s sister company, Univercells Technologies.

Under the terms of the agreement, Exothera will develop the proprietary cell line in the NevoLine and infect them with the GRAd vector to create the bulk vaccine product, which ReiThera will then purify. The viral mass generated after infection will be purified by a process developed by ReiThera.

ReiThera will start with its GRAd vector currently used in its COVID-19 vaccine candidate (GRAd-COV2) for initial process development setup and process it into final form for additional clinical trials at its GMP manufacturing facility.

“This second grant from the Bill & Melinda Gates Foundation, following an initial grant to ReiThera in November 2021 to support the development of the GRAd platform, provides further validation of ReiThera’s innovative technology and underscores our technical expertise in clinical manufacturing and biological risk management. said Stefano Colloca, CTO and co-founder of ReiThera.

“Combining our process know-how with Nevoline from Univercells Technologies will provide low- and middle-income countries with access to much-needed solutions for unmet medical needs such as HIV as well as the current global pandemic. added José Castillo, president of Exothera.


Comments are closed.